留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝内胆管癌肝移植及其综合治疗

吴凤东 史斌

吴凤东, 史斌. 肝内胆管癌肝移植及其综合治疗[J]. 器官移植, 2021, 12(3): 344-350. doi: 10.3969/j.issn.1674-7445.2021.03.014
引用本文: 吴凤东, 史斌. 肝内胆管癌肝移植及其综合治疗[J]. 器官移植, 2021, 12(3): 344-350. doi: 10.3969/j.issn.1674-7445.2021.03.014
Wu Fengdong, Shi Bin. Liver transplantation and comprehensive treatment of intrahepatic cholangiocarcinoma[J]. ORGAN TRANSPLANTATION, 2021, 12(3): 344-350. doi: 10.3969/j.issn.1674-7445.2021.03.014
Citation: Wu Fengdong, Shi Bin. Liver transplantation and comprehensive treatment of intrahepatic cholangiocarcinoma[J]. ORGAN TRANSPLANTATION, 2021, 12(3): 344-350. doi: 10.3969/j.issn.1674-7445.2021.03.014

肝内胆管癌肝移植及其综合治疗

doi: 10.3969/j.issn.1674-7445.2021.03.014
基金项目: 

北京市自然科学基金资助项目 7202235

详细信息
    通讯作者:

    吴凤东,男,1969年生,博士,副主任医师,研究方向为肝移植,Email : 13501080376@163.com

  • 中图分类号: R617, R575.7

Liver transplantation and comprehensive treatment of intrahepatic cholangiocarcinoma

More Information
  • 摘要: 肝移植是治疗肝内胆管癌(ICC)的有效手段,由于ICC侵袭性强、易淋巴结转移,肝移植术后肿瘤复发率较高,需要严格掌握适应证。直径≤2 cm的单发ICC肝移植效果良好,进展期ICC则需先进行包括局部治疗和全身化学药物治疗(化疗)在内的新辅助治疗,根据新辅助治疗的反应决定是否进行肝移植,并于术后进行个体化辅助治疗。目前已经发现多个胆管癌基因突变靶点及靶向治疗药物。肝移植术前、术后辅以综合治疗可拓展ICC肝移植的适应证,改善受者预后。本文从ICC肝移植治疗、ICC肝移植术前新辅助治疗和术后辅助治疗以及ICC靶向治疗等方面进行综述。

     

  • [1] HAND F, HOTI E. Contemporary role of liver transplantation for the treatment of cholangiocarcinoma[J]. Expert Rev Gastroenterol Hepatol, 2020, 14(6): 475-481. DOI: 10.1080/17474124.2020.1765771.
    [2] 李斌, 吕凌, 王学浩. 胆管癌的诊治困境与肝移植进展[J]. 器官移植, 2014, 5(5): 328-330. DOI: 10.3969/j.issn.1674-7445.2014.05.015.

    LI B, LYU L, WANG XH. Trouble of diagnosis and treatment of cholangiocarcinoma and progress on liver transplantation[J]. Organ Transplant, 2014, 5(5): 328-330. DOI: 10.3969/j.issn.1674-7445.2014.05.015.
    [3] 丁义涛. 胆管癌的肝移植治疗策略回顾与展望[J]. 器官移植, 2013, 4(2): 63-67. DOI: 10.3969/j.issn.1674-7445. 2013.02.001.

    DING YT. Retrospect and prospect on the strategy of liver transplantation on cholangiocarcinoma[J]. Organ Transplant, 2013, 4(2): 63-67. DOI: 10.3969/j.issn.1674-7445.2013.02.001.
    [4] MARTIN P, DIMARTINI A, FENG S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation[J]. Hepatology, 2014, 59(3): 1144-1165. DOI: 10.1002/hep.26972.
    [5] European Association for the Study of the Liver. EASL clinical practice guidelines: liver transplantation[J]. J Hepatol, 2016, 64(2): 433-485. DOI: 10.1016/j.jhep.2015. 10.006.
    [6] SAPISOCHIN G, FACCIUTO M, RUBBIA-BRANDT L, et al. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment[J]. Hepatology, 2016, 64(4): 1178-1188. DOI: 10.1002/hep.28744.
    [7] LUNSFORD KE, JAVLE M, HEYNE K, et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series[J]. Lancet Gastroenterol Hepatol, 2018, 3(5): 337-348. DOI: 10.1016/S2468-1253(18)30045-1.
    [8] DE MARTIN E, RAYAR M, GOLSE N, et al. Analysis of liver resection versus liver transplantation on outcome of small intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in the setting of cirrhosis[J]. Liver Transpl, 2020, 26(6): 785-798. DOI: 10.1002/lt.25737.
    [9] FACCIUTO ME, SINGH MK, LUBEZKY N, et al. Tumors with intrahepatic bile duct differentiation in cirrhosis: implications on outcomes after liver transplantation[J]. Transplantation, 2015, 99(1): 151-157. DOI: 10.1097/TP.0000000000000286.
    [10] HEIMBACH JK, GORES GJ, HADDOCK MG, et al. Liver transplantation for unresectable perihilar cholangiocarcinoma[J]. Semin Liver Dis, 2004, 24(2): 201-207. DOI: 10.1055/s-2004-828896.
    [11] HONG JC, JONES CM, DUFFY JP, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center[J]. Arch Surg, 2011, 146(6): 683-689. DOI: 10.1001/archsurg.2011.116.
    [12] WONG M, KIM J, GEORGE B, et al. Downstaging locally advanced cholangiocarcinoma pre-liver transplantation: a prospective pilot study[J]. J Surg Res, 2019, 242: 23-30. DOI: 10.1016/j.jss.2019.04.023.
    [13] GOLDARACENA N, GORGEN A, SAPISOCHIN G. Current status of liver transplantation for cholangiocarcinoma[J]. Liver Transpl, 2018, 24(2): 294-303. DOI: 10.1002/lt.24955.
    [14] GRINGERI E, GAMBATO M, SAPISOCHIN G, et al. Cholangiocarcinoma as an indication for liver transplantation in the era of transplant oncology[J]. J Clin Med, 2020, 9(5): 1353. DOI: 10.3390/jcm9051353.
    [15] MANTEL HT, WESTERKAMP AC, ADAM R, et al. Strict selection alone of patients undergoing liver transplantation for hilar cholangiocarcinoma is associated with improved survival[J]. PLoS One, 2016, 11(6): e0156127. DOI: 10.1371/journal.pone.0156127.
    [16] LEE DD, CROOME KP, MUSTO KR, et al. Liver transplantation for intrahepatic cholangiocarcinoma[J]. Liver Transpl, 2018, 24(5): 634-644. DOI: 10.1002/lt.25052.
    [17] PANJALA C, NGUYEN JH, AL-HAJJAJ AN, et al. Impact of neoadjuvant chemoradiation on the tumor burden before liver transplantation for unresectable cholangiocarcinoma[J]. Liver Transpl, 2012, 18(5): 594-601. DOI: 10.1002/lt.22462.
    [18] PANAYOTOVA GG, PATERNO F, GUARRERA JV, et al. Liver transplantation for cholangiocarcinoma: insights into the prognosis and the evolving indications[J]. Curr Oncol Rep, 2020, 22(5): 49. DOI: 10.1007/s11912-020-00910-1.
    [19] RAYAR M, LEVI SANDRI GB, HOUSSEL-DEBRY P, et al. Multimodal therapy including yttrium-90 radioembolization as a bridging therapy to liver transplantation for a huge and locally advanced intrahepatic cholangiocarcinoma[J]. J Gastrointestin Liver Dis, 2016, 25(3): 401-404. DOI: 10.15403/jgld.2014.1121.253.y90.
    [20] RIZVI S, KHAN SA, HALLEMEIER CL, et al. Cholangiocarcinoma - evolving concepts and therapeutic strategies[J]. Nat Rev Clin Oncol, 2018, 15(2): 95-111. DOI: 10.1038/nrclinonc.2017.157.
    [21] TAO R, KRISHNAN S, BHOSALE PR, et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis[J]. J Clin Oncol, 2016, 34(3): 219-226. DOI: 10.1200/JCO.2015.61.3778.
    [22] HONG TS, WO JY, YEAP BY, et al. Multi-institutional phase Ⅱ study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. J Clin Oncol, 2016, 34(5): 460-468. DOI: 10.1200/JCO.2015.64.2710.
    [23] SAKAMOTO T, TAKEDA Y, OHMURA Y, et al. Treatment outcomes of gemcitabine and cisplatin combination therapy for unresectable and recurrent biliary tract cancer[J]. Gan To Kagaku Ryoho, 2018, 45(13): 2414-2416.
    [24] BENSON AB, D'ANGELICA MI, ABBOTT DE, et al. Guidelines insights: hepatobiliary cancers, version 2.2019[J]. J Natl Compr Canc Netw, 2019, 17(4): 302-310. DOI: 10.6004/jnccn.2019.0019.
    [25] SHROFF RT, JAVLE MM, XIAO L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial[J]. JAMA Oncol, 2019, 5(6): 824-830. DOI: 10.1001/jamaoncol.2019.0270.
    [26] SIA D, HOSHIDA Y, VILLANUEVA A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes[J]. Gastroenterology, 2013, 144(4): 829-840. DOI: 10.1053/j.gastro.2013.01.001.
    [27] NAKAMURA H, ARAI Y, TOTOKI Y, et al. Genomic spectra of biliary tract cancer[J]. Nat Genet, 2015, 47(9): 1003-1010. DOI: 10.1038/ng.3375.
    [28] ROSS JS, WANG K, GAY L, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing[J]. Oncologist, 2014, 19(3): 235-242. DOI: 10.1634/theoncologist.2013-0352.
    [29] KATOH M. Fibroblast growth factor receptors as treatment targets in clinical oncology[J]. Nat Rev Clin Oncol, 2019, 16(2): 105-122. DOI: 10.1038/s41571-018-0115-y.
    [30] JAVLE M, LOWERY M, SHROFF RT, et al. Phase Ⅱ study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma[J]. J Clin Oncol, 2018, 36(3): 276-282. DOI: 10.1200/JCO.2017.75.5009.
    [31] ABOU-ALFA GK, SAHAI V, HOLLEBECQUE A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study[J]. Lancet Oncol, 2020, 21(5): 671-684. DOI: 10.1016/S1470-2045(20)30109-1.
    [32] MAZZAFERRO V, EL-RAYES BF, DROZ DIT BUSSET M, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma[J]. Br J Cancer, 2019, 120(2): 165-171. DOI: 10.1038/s41416-018-0334-0.
    [33] TABERNERO J, BAHLEDA R, DIENSTMANN R, et al. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors[J]. J Clin Oncol, 2015, 33(30): 3401-3408. DOI: 10.1200/JCO.2014.60.7341.
    [34] LOWERY MA, BURRIS HA 3RD, JANKU F, et al. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study[J]. Lancet Gastroenterol Hepatol, 2019, 4(9): 711-720. DOI: 10.1016/S2468-1253(19)30189-X.
    [35] SUN W, PATEL A, NORMOLLE D, et al. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma[J]. Cancer, 2019, 125(6): 902-909. DOI: 10.1002/cncr.31872.
    [36] 王葵, 陈秦俊杰, 夏勇, 等. 肝内胆管癌的外科综合治疗[J]. 临床外科杂志, 2019, 27(8): 638-641. DOI: 10.3969/j.issn.1005-6483.2019.08.003.

    WANG K, CHEN QJJ, XIA Y, et al. Comprehensive treatment of surgical for intrahepatic cholangiocarcinoma[J]. J Clin Surg, 2019, 27(8): 638-641. DOI: 10.3969/j.issn.1005-6483.2019.08.003.
  • 加载中
图(1)
计量
  • 文章访问数:  229
  • HTML全文浏览量:  84
  • PDF下载量:  23
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-02-25
  • 网络出版日期:  2021-05-19
  • 刊出日期:  2021-05-15

目录

    /

    返回文章
    返回